PUBLICATIONS BY THE HUNTINGTON STUDY GROUP

Articles


**Acknowledgements to the Huntington Study Group**

Abstracts


31. Huntington Study Group/PHAROS Investigators (E. Kayson, primary author). Safety and feasibility of the Prospective Huntington At Risk Observational Study (PHAROS): A progress report. Accepted for presentation at the World Congress on Huntington’s Disease, August 16-19, 2003, Toronto, Ontario Canada and published in the program booklet of World Congress on Huntington’s Disease, Abstract #70, page 70, 2003.

32. Huntington Study Group/PHAROS Investigators (K. Biglan, primary author). Emerging cohort characteristics in the Prospective Huntington At Risk Observation Study (PHAROS). Accepted for presentation at the World Congress on Huntington’s Disease, August 16-19, 2003, Toronto, Ontario Canada and published in the program booklet of World Congress on Huntington’s Disease, Abstract #81, page 73, 2003.

33. Huntington Study Group/Predict-HD Investigators (J.S. Paulsen, primary author). Initial baseline characteristics in the Predict-HD (Neurobiological Predictors of HD) Study. Accepted for presentation at the World Congress on Huntington’s Disease, August 16-19, 2003, Toronto, Ontario Canada and published in the program booklet of World Congress on Huntington’s Disease, Abstract #89, page 75, 2003.


41. Huntington Study Group PHAROS Investigators (Kayson EP, presenter). The Features and Well Being of the Prospective Huntington At Risk Observational Study (PHAROS) Cohort. Accepted for presentation at the Hereditary Disease Foundation Summer Symposia (Cambridge, MA, August 2004).

42. Huntington Study Group (HSG) PHAROS Investigators (Shinaman A, presenter). Willingness to Consent for Future Use of Biological Specimens in the Prospective Huntington At Risk Observational Study (PHAROS). Accepted for presentation at the Hereditary Disease Foundation Summer Symposia (Cambridge, MA, August 2004).

at the Hereditary Disease Foundation Summer Symposia (Cambridge, MA, August 2004).


53. Huntington Study Group PHAROS Investigators (Shinaman A, presenter). Willingness to consent for future use of DNA collected in the Prospective Huntington At Risk Observational Study (PHAROS). *Mov Disord* 2006;21(9):1555-1556.


58. Biglan KM, Dorsey ER, Kieburtz K, Ross CA, Hersch S, Shoulson I, Matson W, and the Pre2CARE Investigators of the Huntington Study Group. Serum 80HdG Levels in Manifest Huntington’s Disease and Healthy Controls Treated with Coenzyme Q10. Published in the program booklet of World Congress on Huntington’s Disease 2007, Plenary Session III: S16.


62. Langbehn DR, Paulsen JS, and the PREDICT-HD investigators of the Huntington Study Group. Prospective Validation of CAG-Based Age of Diagnosis in Huntington’s Disease. Published in the program booklet of World Congress on Huntington’s Disease 2007, Clinical Session III: S46.
63. Dorsey ER on behalf of the Huntington Study Group TREND-HD Investigators. A Randomized, Controlled Trial of Ethyl-EPA for the Treatment of Huntington Disease – Preliminary Results. Published in the program booklet of World Congress on Huntington’s Disease 2007, Clinical Session IV: S79.

64. Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K, and the Huntington Study Group PHAROS Investigators. Factors Associated with the Decision to Pursue Genetic Testing in Individuals at Risk for Huntington’s Disease. Published in the program booklet of World Congress on Huntington’s Disease 2007, Abstract P52.

65. Langbehn DR, Paulsen JS, and the PREDICT-HD Investigators of the Huntington Study Group. Prospective Validation of CAG-Based Age of Diagnosis in Huntington’s Disease. Published in the program booklet of World Congress on Huntington’s Disease 2007, Abstract P62.


Group. Serum 80HdG Levels in Manifest Huntington’s Disease and Healthy Controls Treated with Coenzyme Q10. Published in the program booklet of World Congress on Huntington’s Disease 2007, Abstract P148.

72. Dorsey ER on behalf of the Huntington Study Group TREND-HD Investigators. A Randomized, Controlled Trial of Ethyl-EPA for the Treatment of Huntington’s Disease – Preliminary Results. Published in the program booklet of World Congress on Huntington’s Disease 2007, Abstract P150.


88. E. Ray Dorsey, MD, MBA; Christopher A. Beck, PhD; Mary Adams, MTS; Gary Chadwick, PharmD, MPH; Elisabeth A. de Blieck, MPA, CCRC; Colleen McCallum, MSW; Leslie Briner; Lisa Deuel, BA; Anthony Clarke, PhD; Rick Stewart, BS; Ira Shoulson, MD; and the Huntington Study Group TREND-HD Investigators. Communicating Clinical Trial Results to Research Participants. Arch Neurol. 2008; 65(12): 1590-1595.


Functional Outcomes in Early Huntington’s Disease. *Clinical Genetics 2009; 76(Suppl. 1):* 36.


122. Huntington Study Group PHAROS Investigators. Longitudinal Analysis of the UHDRS in Individuals At-Risk for Huntington’s Disease by Gene Status: The Prospective Huntington’s Disease Observational At-Risk Study (PHAROS). *Neurotherapeutics* 2010; 7(1):146.


Reports, Releases, and Position Papers

1. Huntington Study Group To Plan and Carry Out Clinical Trials (November 15, 1993).
3. The Huntington Study Group Moves Forward to Plan and Conduct Clinical Research Trials (August, 1994).
5. HSG Policy on Non-Disclosure of CAG Trinucleotide Repeat Length (CAGn) Genetic (DNA) Information (February 10, 1995).
7. Constitution and Bylaws of the HSG (September 13, 1996).
9. HSG Policy for Storage and Use of Biological Human Research Samples (April 24, 2001).
10. HSG Policy Statement on Publication and Conflict of Interest Pertaining to Clinical Research Involving Persons with Huntington’s Disease (HD) (October 24, 2002).

In Press

